Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate.

Détails

ID Serval
serval:BIB_0DBDDBAB7ACD
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Is atherosclerosis imaging the most sensitive way to assess patients' risk and the best way to conduct future drug trials? A pros-and-cons debate.
Périodique
Atherosclerosis
Auteur(s)
Nanchen D., Raggi P.
ISSN
1879-1484 (Electronic)
ISSN-L
0021-9150
Statut éditorial
Publié
Date de publication
11/2017
Peer-reviewed
Oui
Volume
266
Pages
229-233
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Atherosclerosis imaging has been the focus of intense debate and research for several decades. Among its primary applications are risk stratification of asymptomatic individuals and follow-up of atherosclerosis progression under a variety of treatments designed to retard or regress the development of arterial disease. Although endorsed and supported by many, this approach has been fiercely opposed by several key opinion leaders over the years. Similarly, regulatory agencies have raised a number of objections to resist the approval of new drugs and devices based on surrogate imaging markers. However, there is a large body of evidence in the medical literature that shows that risk stratification is improved with implementation of atherosclerosis imaging. Additionally, numerous lipid-modifying agents have been tested as far as their ability to affect progression of atherosclerosis, and in many cases the information obtained with imaging was in line with the outcome of subsequent clinical trials. This pros-and-cons debate was staged to bring up in a fun and provoking way the main arguments in favour or against the application of atherosclerosis imaging in the main settings described above.
Mots-clé
Asymptomatic Diseases, Atherosclerosis/diagnostic imaging, Atherosclerosis/drug therapy, Atherosclerosis/pathology, Clinical Trials as Topic/methods, Disease Progression, Endpoint Determination, Humans, Hypolipidemic Agents/adverse effects, Hypolipidemic Agents/therapeutic use, Plaque, Atherosclerotic, Predictive Value of Tests, Remission Induction, Research Design, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Atherosclerosis imaging, Atherosclerosis progression, Clinical trial, Coronary artery calcium, Intravascular ultrasound, Screening
Pubmed
Web of science
Création de la notice
02/10/2017 13:12
Dernière modification de la notice
20/08/2019 12:34
Données d'usage